share_log

Avenue Therapeutics | 4: Statement of changes in beneficial ownership of securities-10% Owner Fortress Biotech, Inc.

Avenue Therapeutics | 4: Statement of changes in beneficial ownership of securities-10% Owner Fortress Biotech, Inc.

Avenue Therapeutics | 4：持股变动声明-股东 Fortress Biotech, Inc.
美股sec公告 ·  04/17 16:10
Moomoo AI 已提取核心信息
Fortress Biotech, Inc., reported a completed transaction involving the acquisition of 413,507 shares of common stock in Avenue Therapeutics, Inc. (ATXI) on April 16, 2024. The shares were granted at no cost, as indicated by a transaction price of $0.00. Following this transaction, Fortress Biotech's direct holdings in Avenue Therapeutics increased to a total of 3,547,393 shares. The nature of the transaction was described as a grant, award, or other acquisition, according to the transaction code 'A'. This event reflects a significant increase in Fortress Biotech's stake in the pharmaceutical company.
Fortress Biotech, Inc., reported a completed transaction involving the acquisition of 413,507 shares of common stock in Avenue Therapeutics, Inc. (ATXI) on April 16, 2024. The shares were granted at no cost, as indicated by a transaction price of $0.00. Following this transaction, Fortress Biotech's direct holdings in Avenue Therapeutics increased to a total of 3,547,393 shares. The nature of the transaction was described as a grant, award, or other acquisition, according to the transaction code 'A'. This event reflects a significant increase in Fortress Biotech's stake in the pharmaceutical company.
Fortress Biotech, Inc. 报告称，一项交易已于2024年4月16日完成，涉及收购Avenue Therapeutics, Inc.（ATXI）413,507股普通股。这些股票是免费授予的，交易价格为0.00美元。在这笔交易之后，丰泽生物科技在Avenue Therapeutics的直接持股量增加到总共3547,393股。根据交易代码 “A”，该交易的性质被描述为赠款、奖励或其他收购。该事件反映了丰泽生物科技在这家制药公司的股份大幅增加。
Fortress Biotech, Inc. 报告称，一项交易已于2024年4月16日完成，涉及收购Avenue Therapeutics, Inc.（ATXI）413,507股普通股。这些股票是免费授予的，交易价格为0.00美元。在这笔交易之后，丰泽生物科技在Avenue Therapeutics的直接持股量增加到总共3547,393股。根据交易代码 “A”，该交易的性质被描述为赠款、奖励或其他收购。该事件反映了丰泽生物科技在这家制药公司的股份大幅增加。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息